Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.

Farokhnia, Mehdi; Rentsch, Christopher T; Chuong, Vicky; McGinn, M Adrienne; Elvig, Sophie K; Douglass, Eliza A; Gonzalez, Luis A; Sanfilippo, Jenna E; Marchette, Renata CN; Tunstall, Brendan J; +5 more... Fiellin, David A; Koob, George F; Justice, Amy C; Leggio, Lorenzo; Vendruscolo, Leandro F; (2022) Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry, 27 (11). pp. 4642-4652. ISSN 1359-4184 DOI: https://doi.org/10.1038/s41380-022-01736-y

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1038/s41380-022-01736-y

Abstract

Share

Download

Filename: Farokhnia_etal_2022_Spironolactone-as-a-potential-new.pdf

Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar